PSNL - Personalis, Inc.
IEX Last Trade
6.28
0.140 2.229%
Share volume: 14,978
Last Updated: Thu 26 Dec 2024 08:30:15 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$6.14
0.14
2.28%
Fundamental analysis
21%
Profitability
2%
Dept financing
10%
Liquidity
75%
Performance
30%
Performance
5 Days
2.35%
1 Month
63.27%
3 Months
18.02%
6 Months
411.76%
1 Year
248.00%
2 Year
230.98%
Key data
Stock price
$6.28
DAY RANGE
$5.78 - $6.26
52 WEEK RANGE
$1.19 - $7.20
52 WEEK CHANGE
$159.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: John S. West
Region: US
Website: personalis.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: personalis.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Personalis, Inc. operates as a cancer genomics company worldwide. It provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection.
Recent news